Kleiton Silva Borges, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Adrenal Cortex Neoplasms | 8 | 2024 | 161 | 2.000 |
Why?
|
Adrenocortical Carcinoma | 6 | 2024 | 88 | 1.550 |
Why?
|
Supratentorial Neoplasms | 3 | 2023 | 159 | 1.140 |
Why?
|
Ependymoma | 3 | 2023 | 320 | 1.000 |
Why?
|
Transcription Factor RelA | 3 | 2023 | 254 | 0.740 |
Why?
|
Phthalazines | 3 | 2021 | 383 | 0.730 |
Why?
|
beta Catenin | 3 | 2023 | 1042 | 0.640 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2020 | 2915 | 0.600 |
Why?
|
Protein Kinase Inhibitors | 4 | 2020 | 5662 | 0.530 |
Why?
|
Benzamides | 4 | 2021 | 1371 | 0.520 |
Why?
|
Receptors, Notch | 1 | 2019 | 743 | 0.470 |
Why?
|
Glioblastoma | 4 | 2020 | 3482 | 0.460 |
Why?
|
Neoplastic Stem Cells | 1 | 2019 | 1348 | 0.380 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2013 | 349 | 0.360 |
Why?
|
Apoptosis | 10 | 2020 | 9477 | 0.350 |
Why?
|
Dacarbazine | 2 | 2013 | 559 | 0.340 |
Why?
|
Quinazolines | 2 | 2013 | 1371 | 0.310 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2011 | 617 | 0.290 |
Why?
|
Gene Expression Regulation, Neoplastic | 9 | 2024 | 8530 | 0.290 |
Why?
|
Antineoplastic Agents | 8 | 2020 | 13632 | 0.270 |
Why?
|
Cytidine | 2 | 2016 | 60 | 0.250 |
Why?
|
DNA Modification Methylases | 2 | 2016 | 210 | 0.230 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 1549 | 0.230 |
Why?
|
Glypicans | 1 | 2023 | 33 | 0.220 |
Why?
|
Drug Synergism | 5 | 2021 | 1756 | 0.200 |
Why?
|
Adrenal Insufficiency | 1 | 2023 | 194 | 0.190 |
Why?
|
Disease Models, Animal | 1 | 2020 | 18220 | 0.180 |
Why?
|
Cell Proliferation | 8 | 2021 | 10422 | 0.180 |
Why?
|
Medulloblastoma | 2 | 2016 | 677 | 0.180 |
Why?
|
Leukemia, Lymphoid | 1 | 2020 | 311 | 0.170 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2020 | 98 | 0.170 |
Why?
|
Cell Line, Tumor | 11 | 2021 | 16952 | 0.170 |
Why?
|
Wnt Proteins | 1 | 2023 | 720 | 0.170 |
Why?
|
Adrenal Hyperplasia, Congenital | 1 | 2020 | 98 | 0.160 |
Why?
|
Mitotane | 1 | 2017 | 20 | 0.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 11733 | 0.140 |
Why?
|
Brain Neoplasms | 4 | 2015 | 9025 | 0.140 |
Why?
|
Gene Expression Profiling | 5 | 2024 | 9416 | 0.140 |
Why?
|
Multigene Family | 1 | 2020 | 1075 | 0.140 |
Why?
|
Pluripotent Stem Cells | 1 | 2023 | 794 | 0.140 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6486 | 0.130 |
Why?
|
Receptor, Notch1 | 1 | 2019 | 497 | 0.130 |
Why?
|
Garcinia | 1 | 2015 | 3 | 0.130 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 1 | 2016 | 151 | 0.130 |
Why?
|
Cisplatin | 3 | 2017 | 1652 | 0.130 |
Why?
|
Benzophenones | 1 | 2015 | 57 | 0.130 |
Why?
|
Benzoquinones | 1 | 2015 | 198 | 0.120 |
Why?
|
Germ-Line Mutation | 2 | 2020 | 1852 | 0.120 |
Why?
|
Calcium-Binding Proteins | 1 | 2019 | 1067 | 0.120 |
Why?
|
Methotrexate | 3 | 2022 | 1718 | 0.120 |
Why?
|
Up-Regulation | 2 | 2021 | 4111 | 0.110 |
Why?
|
Doxorubicin | 2 | 2017 | 2224 | 0.100 |
Why?
|
RNA-Binding Proteins | 1 | 2021 | 1855 | 0.100 |
Why?
|
Cyclohexanones | 1 | 2012 | 30 | 0.100 |
Why?
|
Prognosis | 6 | 2024 | 29687 | 0.100 |
Why?
|
Sp1 Transcription Factor | 1 | 2013 | 140 | 0.100 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 479 | 0.100 |
Why?
|
Genes, bcl-2 | 1 | 2012 | 119 | 0.100 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2013 | 198 | 0.100 |
Why?
|
Plant Extracts | 1 | 2015 | 496 | 0.100 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2015 | 620 | 0.100 |
Why?
|
Cerebellar Neoplasms | 1 | 2016 | 586 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3592 | 0.100 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2014 | 221 | 0.090 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2014 | 651 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2020 | 2871 | 0.090 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2015 | 774 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2017 | 10756 | 0.090 |
Why?
|
Histones | 2 | 2017 | 2570 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3594 | 0.080 |
Why?
|
Phosphorylation | 2 | 2017 | 8300 | 0.080 |
Why?
|
RNA, Neoplasm | 1 | 2011 | 748 | 0.080 |
Why?
|
Cilia | 1 | 2023 | 495 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2813 | 0.080 |
Why?
|
Humans | 25 | 2024 | 761208 | 0.080 |
Why?
|
Hedgehog Proteins | 1 | 2023 | 769 | 0.070 |
Why?
|
Mice, Knockout | 2 | 2020 | 14392 | 0.070 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 1132 | 0.070 |
Why?
|
Mice, Transgenic | 1 | 2020 | 9520 | 0.070 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2011 | 1168 | 0.070 |
Why?
|
Child, Preschool | 7 | 2024 | 42224 | 0.070 |
Why?
|
Histone Deacetylases | 1 | 2011 | 716 | 0.070 |
Why?
|
Astrocytoma | 1 | 2011 | 774 | 0.070 |
Why?
|
Osteosarcoma | 1 | 2012 | 896 | 0.070 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 2803 | 0.070 |
Why?
|
Brazil | 2 | 2020 | 1228 | 0.060 |
Why?
|
Sequence Analysis, RNA | 2 | 2024 | 2011 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 4567 | 0.060 |
Why?
|
Blotting, Western | 1 | 2011 | 5032 | 0.060 |
Why?
|
RNA, Messenger | 3 | 2014 | 12747 | 0.060 |
Why?
|
Receptors, Corticotropin | 1 | 2023 | 24 | 0.060 |
Why?
|
NF-kappa B | 1 | 2012 | 2475 | 0.060 |
Why?
|
Frizzled Receptors | 1 | 2023 | 91 | 0.050 |
Why?
|
Infant | 5 | 2024 | 36169 | 0.050 |
Why?
|
Vincristine | 2 | 2016 | 1036 | 0.050 |
Why?
|
Disease-Free Survival | 1 | 2013 | 6819 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 3702 | 0.050 |
Why?
|
Mitotic Index | 2 | 2013 | 162 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2019 | 7851 | 0.050 |
Why?
|
Child | 8 | 2024 | 80152 | 0.050 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2023 | 617 | 0.050 |
Why?
|
Animals | 4 | 2022 | 168079 | 0.050 |
Why?
|
Adenoma | 1 | 2012 | 2159 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2012 | 4340 | 0.050 |
Why?
|
Choroid Plexus Neoplasms | 1 | 2020 | 38 | 0.040 |
Why?
|
Daunorubicin | 1 | 2020 | 157 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2011 | 2974 | 0.040 |
Why?
|
Bone Neoplasms | 1 | 2012 | 2527 | 0.040 |
Why?
|
Immunohistochemistry | 1 | 2013 | 11067 | 0.040 |
Why?
|
Cell Transdifferentiation | 1 | 2020 | 186 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2013 | 7571 | 0.040 |
Why?
|
Embryonic Development | 1 | 2023 | 719 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2013 | 12474 | 0.040 |
Why?
|
Cell Survival | 2 | 2021 | 5778 | 0.040 |
Why?
|
Mice, Inbred NOD | 1 | 2022 | 1822 | 0.040 |
Why?
|
Cells, Cultured | 1 | 2013 | 18926 | 0.040 |
Why?
|
Rhabdomyosarcoma | 1 | 2020 | 358 | 0.040 |
Why?
|
DNA Methylation | 1 | 2011 | 4384 | 0.030 |
Why?
|
Steroids | 1 | 2021 | 929 | 0.030 |
Why?
|
Cell Cycle | 2 | 2015 | 2925 | 0.030 |
Why?
|
Gene Regulatory Networks | 1 | 2024 | 1743 | 0.030 |
Why?
|
Adolescent | 4 | 2024 | 88298 | 0.030 |
Why?
|
ras Proteins | 1 | 2020 | 1055 | 0.030 |
Why?
|
Point Mutation | 1 | 2020 | 1593 | 0.030 |
Why?
|
Epigenesis, Genetic | 2 | 2023 | 3788 | 0.030 |
Why?
|
Drug Antagonism | 1 | 2014 | 51 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 361 | 0.030 |
Why?
|
Female | 9 | 2024 | 392544 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2023 | 2159 | 0.030 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2015 | 197 | 0.030 |
Why?
|
Male | 8 | 2024 | 360693 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2020 | 1480 | 0.030 |
Why?
|
Lipids | 1 | 2023 | 3331 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 1 | 2013 | 464 | 0.020 |
Why?
|
Drug Interactions | 1 | 2016 | 1417 | 0.020 |
Why?
|
Chromatin | 1 | 2023 | 2946 | 0.020 |
Why?
|
Cell Hypoxia | 1 | 2014 | 656 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 22140 | 0.020 |
Why?
|
Methylation | 1 | 2014 | 1070 | 0.020 |
Why?
|
Colony-Forming Units Assay | 1 | 2011 | 351 | 0.020 |
Why?
|
DNA Damage | 1 | 2020 | 2442 | 0.020 |
Why?
|
Genes, Neoplasm | 1 | 2012 | 370 | 0.020 |
Why?
|
Time Factors | 1 | 2011 | 39957 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2012 | 714 | 0.020 |
Why?
|
Azacitidine | 1 | 2011 | 336 | 0.020 |
Why?
|
Carcinoma | 1 | 2020 | 2330 | 0.020 |
Why?
|
RNA Splicing | 1 | 2013 | 896 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2016 | 3777 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2014 | 1749 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2011 | 646 | 0.020 |
Why?
|
Cohort Studies | 2 | 2020 | 41496 | 0.020 |
Why?
|
Protein Transport | 1 | 2012 | 1958 | 0.020 |
Why?
|
Adult | 5 | 2022 | 221119 | 0.020 |
Why?
|
Tumor Burden | 1 | 2012 | 1892 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2011 | 1743 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 1404 | 0.020 |
Why?
|
Age of Onset | 1 | 2012 | 3307 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2016 | 3446 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2015 | 6304 | 0.020 |
Why?
|
Down-Regulation | 1 | 2012 | 2916 | 0.010 |
Why?
|
Mice | 2 | 2022 | 81326 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2012 | 4851 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2011 | 6124 | 0.010 |
Why?
|
Gene Expression | 1 | 2015 | 7571 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 22127 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 6067 | 0.010 |
Why?
|
Cell Movement | 1 | 2012 | 5195 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2014 | 5300 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2016 | 26199 | 0.010 |
Why?
|
Young Adult | 1 | 2016 | 59221 | 0.010 |
Why?
|
Middle Aged | 1 | 2021 | 220853 | 0.000 |
Why?
|
Brain | 1 | 2011 | 27092 | 0.000 |
Why?
|